David S. Rosenthal Email & Phone Number

I am the former co-chair of both Dechert’s Life Sciences Practice and its Global Corporate Finance Practice. I advise publicly and privately held corporations and investment banks in the life sciences and medical device, technology and other growth sectors. I represent issuers and investment banks in public and private offerings of equity and debt, including IPOs, secondary offerings, confidentially marketed public offerings (CMPOs), at-the-market (ATM) financings, registered direct offerings and PIPEs, as well as venture capital financings. I regularly handle Securities and Exchange Commission compliance and corporate governance matters and often act as outside general corporate and securities counsel to both emerging and publicly traded companies. I have also represented clients in mergers and acquisitions, joint ventures, licensing and strategic alliances, and have counseled foreign private issuers in migrating to and listing on the U.S. stock exchanges. In the mergers and acquisitions area, I represent buyers and sellers in leveraged and unleveraged mergers, and acquisitions, as well as dispositions of business and subsidiaries.I am routinely recognized by The Legal 500 US for my work in the life sciences industry, most recently in 2024, as well as for capital markets: equity, debt and global offerings by. Clients have noted that I am “truly exceptional” and someone who “stands out in his field” and “carefully researches matters of relevance." In The Legal 500 US, clients have also praised me as “a trusted and valued advisor” who “seeks to understand the client’s business”, as well as for my “clear and well-reasoned positions” and my “business-minded approach.” I also been noted for having “an active life sciences roster” with “an immense depth of industry and transactional knowledge in the healthcare sector.” In 2022, I led the team commended by the Financial Times’ Innovative Lawyer Awards for “overcoming barriers to investment and finance” for its role in Tiziana Life Sciences’ cross-border jurisdictional migration from listing on the London Stock Exchange to the NASDAQ. I am consistently named an LMG Life Sciences Star for life sciences transactions. In 2020, I was named a “Dealmaker of the Year” by The American Lawyer for my work conceiving and executing an innovative life sciences restructuring deal on behalf of pharmaceuticals manufacturer Egalet Corporation . In addition, I am routinely recognized as a leading life sciences transactional lawyer by Who’s Who Legal: USA and was named a “highly regarded” lawyer for M&A in the IFLR1000.

Listed skills include Venture Capital and Securities Regulation.